{
    "biomarker_id": "BB3854-1",
    "biomarker_canonical_id": "BB3854",
    "condition": {
        "recommended_name": {
            "id": "DOID:3910",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:3910",
            "name": "lung adenocarcinoma",
            "description": "A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin."
        },
        "synonyms": [
            {
                "id": "DOID:3910",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:3910",
                "name": "bronchogenic lung adenocarcinoma",
                "description": ""
            },
            {
                "id": "DOID:3910",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:3910",
                "name": "nonsmall cell adenocarcinoma",
                "description": ""
            }
        ],
        "id": "DOID:3910"
    },
    "biomarker_component": [
        {
            "biomarker": "decreased level of F1H5N4S1 on IQGAP1",
            "assessed_biomarker_entity_id": "P46940-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Ras GTPase-activating-like protein IQGAP1",
                "synonyms": [
                    {
                        "synonym": "p195"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "tissue",
                    "namespace": "UBERON",
                    "id": "0000479",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0000479",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "BB3854-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/BB3854-1"
                },
                {
                    "id": "40175289",
                    "database": "PubMed",
                    "url": "",
                    "tags": [
                        "assessed_biomarker_entity_id",
                        " assessed_biomarker_entiy",
                        " assessed_entity_type",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "For example, the increase of N197/553 H3N2 and H5N2 on CEAM5 in tumor regions can be partially due to the overexpression of CEAM5 itself; on the other hand, the decrease of IQGA1 N1449 F1H5N4S1 is likely affected only by N-glycosylation events. 57 We have not detected changes in IQGA1 expression, but we have found that the abundance of the N-glycopeptide N1449 F1H5N4S1 decreased substantially in TWT LUAD. Additionally, the novel glycosylation site of IQGAP1 protein (N1449) where a decrease in glycopeptide abundance was observed is also interesting as a possible intervention point as this glycoprotein can be linked with sustained proliferative signaling, an important hallmark of cancer. We confirmed and detected changes in glycosylation on previously unconfirmed N-glycosylation sites, for example the substantial decrease of the N-glycopeptide N1449 F1H5N4S1 of IQGA1, a glycoprotein with high oncogenic potential."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": ""
        }
    ],
    "evidence_source": [
        {
            "id": "BB3854-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3854-1"
        },
        {
            "id": "40175289",
            "database": "PubMed",
            "url": "",
            "tags": [
                "condition"
            ],
            "evidence_list": [
                {
                    "evidence": "For example, the increase of N197/553 H3N2 and H5N2 on CEAM5 in tumor regions can be partially due to the overexpression of CEAM5 itself; on the other hand, the decrease of IQGA1 N1449 F1H5N4S1 is likely affected only by N-glycosylation events. 57 We have not detected changes in IQGA1 expression, but we have found that the abundance of the N-glycopeptide N1449 F1H5N4S1 decreased substantially in TWT LUAD. Additionally, the novel glycosylation site of IQGAP1 protein (N1449) where a decrease in glycopeptide abundance was observed is also interesting as a possible intervention point as this glycoprotein can be linked with sustained proliferative signaling, an important hallmark of cancer. We confirmed and detected changes in glycosylation on previously unconfirmed N-glycosylation sites, for example the substantial decrease of the N-glycopeptide N1449 F1H5N4S1 of IQGA1, a glycoprotein with high oncogenic potential."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "BB3854-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3854-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 0
                }
            ],
            "sort_fields": []
        }
    ]
}